• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 19, 2017

View Archived Issues

News items three in DMD: Capricor PRV meant to be? Biomarin, Sarepta settle up

In a big news day for Duchenne muscular dystrophy (DMD) companies, Capricor Therapeutics Inc. CEO Linda Marbán told BioWorld that investors will "see news coming in the next week or two with a clearly delineated path to registration" for CAP-1002. "We have a trial design; we have a plan on what has to be done." Read More

In the clinic

Brainstorm Cell Therapeutics Inc., of Hackensack, N.J., said it signed definitive agreements with Massachusetts General Hospital and California Pacific Medical Center to enroll patients in the planned phase III trial of stem cell therapy candidate Nurown in amyotrophic lateral sclerosis, pending FDA and institutional review board approvals. Read More

Other news to note

Biondvax Pharmaceuticals Ltd., of Ness Ziona, Israel, signed an agreement to lease space in the Jerusalem Biopark, located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University's Medical School. Read More

Sound of statutory silence echoes throughout 340B program

"The statute is silent" was the Health Resources and Services Administration's (HRSA) constant refrain Tuesday in a House subcommittee hearing on the growth and oversight of the 340B prescription drug discount program. Read More

Menlo itching to solve pruritus with $50M round for serlopitant

Menlo Therapeutics Inc. added new faces to its stable of investors in a $50 million series C designed to move serlopitant, the company's NK-1 receptor antagonist, into a pivotal program as a once-daily oral treatment for the lead indication of chronic pruritus, or itch, associated with the skin disease prurigo nodularis. The company, aptly based in Menlo Park, Calif., also is advancing serlopitant to treat chronic pruritus associated with the broader indications of atopic dermatitis and psoriasis and to treat refractory chronic cough. Read More

Academics, payers suggest closing loopholes as FDA considers how to improve generics market

FDA staffers gathered to hear advice on better balancing support for new drug development with efforts to speed access to lower-cost generics got an earful from generics companies, payers and their representatives about how loopholes, citizen petitions and market gaming have left the balance of power tilted toward innovators. Read More

Cstone to start clinical trials of breakthrough cancer drug

HONG KONG – Cstone Pharmaceuticals Co. Ltd. has received the go-ahead from the CFDA to conduct clinical trials with its investigational agent, CS-1001, making it the first company in China to successfully have a fully human, full-length anti-PD-L1 monoclonal antibody enter clinical development. Read More

Puma's Nerlynx approved as extended adjuvant breast cancer therapy

Despite some skepticism heading toward the July 21 PDUFA date, Puma Biotechnology Inc.'s breast cancer drug, Nerlynx (neratinib), won FDA approval a few days early, marking the first treatment designated as an extended adjuvant therapy in patients with early stage, HER2-positive disease. Read More

Financings

Cymabay Therapeutics Inc., of Newark, Calif., said it intends to offer and sell 10 million shares of its common stock, subject to market and other conditions, in an underwritten public offering. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • AI-generated illustration of CAR T cells

    Researchers arm CAR T cells to fight solid tumors

    BioWorld
    Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
  • Digital lungs illustration

    Bioversys, Shionogi in CHF529M lung infection collaboration

    BioWorld Science
    Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
  • Medtronic Vitalflow ECMO

    Medtronic receives CE mark for its Vitalflow ECMO system

    BioWorld MedTech
    Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe